Feb 28, 2022 / 03:00PM GMT
Operator
Good afternoon, and welcome to the Oncimmune Holdings plc interim-results investor presentation. (Operator Instructions)
I'd now like to hand you over to Dr. Adam Hill, CEO; Matthew Hall, CFO. Good afternoon.
Adam Hill - Oncimmune Holdings plc - CEO
Good afternoon, everyone, and thank you very much, [Paul], for the introduction. Welcome all to Oncimmune interim-results and progress update. Today, apologies for my croaky voice. Myself and Matthew, CEO and CFO, respectively, of course, who you've met before, many of you, will be presenting today.
In the first instance, I'll walk through commercial updates on both our service business and our product business before handing over to Matthew to walk through the finances from announcement this morning, and then we'll end with the outlook. Just to remind you all, Oncimmune is a business that is specialist in the use of autoantibodies for the detection of binding events between antigen or proteins that cause an immune response and the antibodies.
We have three sets of tools that we use in
Half Year 2022 Oncimmune Holdings PLC Earnings Call Transcript
Feb 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers